Results 151 to 160 of about 94,347 (282)

Advanced extracellular vesicle immunotherapy

FlexMat, EarlyView.
A diagrammatic depiction of the therapeutic applicability of extracellular vesicles (EVs) in immunotherapy. This review explores the dual roles of tumor‐derived and immune cell‐derived EVs in cancer immunotherapy, discusses recent progress in EV engineering that improve their clinical utility, and evaluates their potential to augment existing ...
Jingjing Zhang, Yunfei Mu, Xianyue Ji, Xiaoting Jiang, Ruiheng Wang, Xianguang Ding, Lianhui Wang   +6 more
wiley   +1 more source

Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma

Head &Neck, EarlyView.
ABSTRACT Purpose Olfactory neuroblastoma (ONB) is a rare sinonasal malignancy with limited therapeutic options in the recurrent/metastatic setting; little is known regarding its responsiveness to immunotherapy. Inhibition of enhancer of zeste homolog 2 (EZH2) has been shown to improve T‐cell‐mediated killing and susceptibility to immune checkpoint ...
Elisabetta Xue, Tolulope Adeyelu, Harris Krause, Andrew Elliott, Ranee Mehra, Heloisa Soares, Emil Lou, Ari Vanderwalde, David Spetzler, Dara Bracken‐Clarke, Nyall R. London Jr., James L. Gulley, Charalampos S. Floudas   +12 more
wiley   +1 more source

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

International Journal of Cancer, EarlyView.
What's New? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel, Linus Materna, Ramona Stelmach, Stefanie Zschäbitz, Stephanie Neuberger, Can D. Aydogdu, Jozefina Casuscelli, Timo Egenolf, Matteo Silberg, Julie Steinestel, Arne Strauss, Florian Kirchhoff, Marit Ahrens, Pia Paffenholz, Richard Cathomas, Berna C. Özdemir, Christopher Gossler, Philipp Ivanyi, Marc Rehlinghaus, Thomas Hilser, Viktor Grünwald, Katrin Schlack   +21 more
wiley   +1 more source

Organ‐sparing strategies in patients with MSI/dMMR tumors including Lynch syndrome: Current state of the art and future perspectives for clinical decision‐making

International Journal of Cancer, EarlyView.
Abstract Deficiency in DNA mismatch repair (dMMR) is a common pathway of carcinogenesis across different tumor types and confers a characteristic microsatellite instability‐high (MSI‐H) molecular phenotype. The MSI‐H/dMMR phenotype may arise from an inherited pathogenic variant in the context of Lynch syndrome and is most frequently observed in ...
Martin Duval, Antoine Dardenne, Thomas Samaille, Leo Mas, Jérémie H. Lefèvre, Xavier Dray, Mathilde Wagner, Romain Cohen, Thierry André   +8 more
wiley   +1 more source

Immunotherapy in advanced gastroesophageal cancers: A meta‐analysis of sex‐based outcomes in overall survival

International Journal of Cancer, EarlyView.
What's New? Immune checkpoint inhibitors (ICIs) improve survival in advanced gastroesophageal cancer (GEC), but their benefits may differ by sex. Little is known, however about the impact of sex‐related immune differences on ICI efficacy. In this meta‐analysis, sex‐specific outcomes of ICI therapy were evaluated in advanced GEC, encompassing both ...
Michael Masetti, Fausto Petrelli, Filippo Pietrantonio, Sylvie Lorenzen, Alberto Giovanni Leone   +4 more
wiley   +1 more source

A Pan‐Cancer Microenvironment Atlas Constructed by DECEPTICONx

iMetaMed, EarlyView.
DECEPTICONx builds the most comprehensive pan‐cancer TME atlas to date from > 11,000 TCGA samples using 535,665 single cells, revealing 102 immune/stromal subtypes with robust novel associations to patient outcomes, immunotherapy response, and intercellular coordination in the TME.
Yida Gu, Fulan Deng, Lianchong Gao, Zhiyu Chen, Jianping Chen, Jiale Wu, Zengqiang Xia, Zhijian Li, Fangkaikai Cheng, Jie Chen, Henry H. Y. Tong, Wantao Chen, Xiaoqing Pan, Xin Zou, Jie Hao   +14 more
wiley   +1 more source

Targeting Microbiome Metabolites: Reshaping Immunotherapy and Clinical Management Strategies for Colorectal Cancer

iMetaMed, EarlyView.
The occurrence and progression of colorectal cancer are intricately linked to metabolites produced by the gut microbiota. Metabolites generated by pathogenic microbial communities can promote colorectal cancer development by reshaping the immune microenvironment.
Xinrui Yang, Ke Zhang, Lijie Xia, Jinyao Li   +3 more
wiley   +1 more source

Microbial influences on immune modulation and colorectal cancer progression through combined transcriptomic and microbiomic analysis

iMetaOmics, EarlyView.
Schematic representation of the distinct tumor microenvironment characteristics in CA1 and CA2 subtypes. CA1 illustrates an immune‐active tumor microenvironment characterized by elevated infiltration of immune cells, particularly CD8 + T cells and macrophages, and enhanced IFN‐γ signaling.
Shuting Xia, Likun Wang, Yangzhuo Xu, Jiaqi Zhang, Zeyang Zhou, Libing Sun, Heng Li, Chungen Xing, Jialu Mao, Yina Liu, Fulin Yang, Ling Zhong, Jiancheng Xu, Xiaodong Yang, Zhemin Zhou   +14 more
wiley   +1 more source

PD‐1/PD‐L1 in Hepatocellular Carcinoma (2014–2024): A Combined Macro and Micro Analysis of Immunotherapy Implications

iNew Medicine, EarlyView.
ABSTRACT Hepatocellular carcinoma (HCC) represents a significant global health issue, with the PD‐1/PD‐L1 axis serving a pivotal target for immunotherapy in this malignancy. However, a comprehensive bibliometric analysis of PD‐1/PD‐L1 research in HCC is lacking.
Xingyu Zhu, Lin Tang, Hongyan Li, Hao Li, Jiamei Wang   +4 more
wiley   +1 more source

Napabucasin transforms liver microenvironment and boosts immunotherapy efficacy by converting potential metastases into “hot” tumors

Interdisciplinary Medicine, EarlyView.
Napabucasin reduces liver metastases by reprogramming the hepatic microenvironment. It induces hepatocyte secretion of CCL21 via c‐Fos activation, recruiting lymphocytes and converting “cold” metastases into immunologically “hot” tumors. This effect is liver‐specific and independent of cancer cells.
Qiongqiong Wang, Jiaqi Zhou, Hang Qiao, Yifan Jia, Ling Ye, Zeli Li, Jiahe Ouyang, Haoxian Zhou, Kangxin Zeng, Xuemeng Wang, Yixian Wang, Yang Zhang, Yupeng Zhang, Yizhou Cai, Yutao Hu, Minzhe Zhang, Wenwei Xu, Zhenzhen Wu, Xiaofang Qiu, Li Lin   +19 more
wiley   +1 more source